Optimized LDR regimens and their combination with fibroblast growth factor-21 (FGF21) further amplify these systemic benefits by addressing key factors such as dyslipidemia, insulin resistance, and diabetes-induced renal pathology. Here, FGF21 is linked to metabolic syndrome.